协议说明
提示

阅读并同意隐私协议、MTA和使用条款后进行下一步!

Genome
Total Investment Exceeds 300 Million RMB, World's Largest in vitro Synthetic Protein Factory

The Total Investment Exceeds 300 Million RMB, and the World's largest in vitro Synthetic Protein Factory Settled in Minhang, Shanghai, China, District.

Original Article "Area Investment Promotion Center - Investment Minhang District, Shanghai, China. "2022-06-24 19:00 Published in Shanghai, China.

Recently, Kangma-Healthcode (SH) Biotechnology Co., Ltd. completed the industrial factory transfer in the Minhang Economic and Technological Development Zone, which represents the official construction of a 160 -ton D2P protein production base with a total investment of 200 Million RMB.

Settled in Minhang, Shanghai, China, District, Development Zone Build the World's Largest in vitro Synthetic Protein Factory.

After the completion of the project, it will become the world's largest cell -free in vitro synthetic protein capacity factory, and achieves the first 100 -ton -level protein synthetic industrialization demonstration factories in the world.

Meanwhile, Kangma-Healthcode (SH) Biotechnology Co., Ltd. will also invest 120 Million RMB in Minhang, Shanghai, China economic and Technological Development Zone to build a 13000 ㎡ biological innovative drug research and development pilot base. The project has entered the GMP design review stage. The base will focus on the R & D and pilot test of new and innovative drugs such as protein blockers, antibacterial peptides and artificial hemoglobin.

In the future, with the support of the Government of Minhang District, Shanghai, China, and the Minhang District, Shanghai, Economic and Technological Development Zone, the Kangma-Healthcode (SH) Biotechnology Co., Ltd. Plan will build 3 to 5 large biopharmaceutical production bases in Minhang, Shanghai, China, District, and at the same time Increase the output value of Protein Raw Materials to more than 1 Billion RMB.

Company Profile

Kangma-Healthcode (SH) Biotechnology Co., Ltd. was founded in 2015. It is a high-tech enterprise integrating DNA-to-Protein underlying technology (hereinafter referred to as D2P technology), biomedical innovative product research and development, and protein sequence intelligence algorithm. During the epidemic, Kansetin™ blocking protein is one of the industrialization results of the company's D2P technology. After 6 years of D2P technology accumulation, the company has now realized industrialized protein synthesis and is widely used in the fields of IVD in vitro testing, drug screening, biomedicine, public epidemic prevention and medical beauty.

https://mp.weixin.qq.com/s/PztK02reY2mCcYMoKWRp8Q
FOOT
更多联系方式,上海市浦东新区芙蓉花路118弄12-15号楼,请拨打 +1-800-955 -3390or+86-400-770-5500周一到周日 0:00-24:00

沪公网安备 31011502014489号

©2015-2024 Kangma-Healthcode. All Rights Reserved. 隐私政策使用条款销售和退款法律网站地图
中国